This workshop is designed to help regulatory and product development teams successfully bring AI/ML-enabled medical devices to market. You will learn global reg. perspectives from the US FDA, EU MDR and China NMPA.
As artificial intelligence (AI) and machine learning (ML) continue to transform healthcare, regulatory professionals must navigate increasingly complex and rapidly evolving global requirements. This workshop provides a unified, comprehensive guide to both international regulatory frameworks and early regulatory engagement strategies, equipping participants with the tools to bring AI/ML-enabled medical devices to market efficiently and compliantly.
Participants will explore the regulatory landscapes of the US FDA, EU MDR, and China NMPA, comparing classification pathways, documentation expectations, clinical evidence requirements, and key guidance documents. The workshop also emphasizes the critical role of early and continuous regulatory affairs (RA) involvement in AI product development, demonstrating how proactive regulatory strategy can reduce risk, streamline design decisions, and prevent delays in FDA submissions.
Drawing from real-world case studies and FDA interactions, the session will highlight common pitfalls—such as data quality issues, insufficient algorithm validation, and gaps in cybersecurity or change management documentation—and show how early planning can avoid them. Attendees will learn practical methods for aligning technical teams with regulatory expectations, integrating ethical and data governance considerations, and building robust submissions tailored to each region.
This workshop is designed for regulatory professionals, R&D leaders, and cross‑functional teams who want to stay ahead of global AI regulatory trends and accelerate successful market entry through smarter, proactive regulatory strategy.
Upon completion of this workshop, participants will be able to:
Intermediate: Content is designed based upon the assumption that individuals have basic knowledge of the topic(s) and/or demonstrated competence related to the topic(s). Higher-level concepts are introduced during lectures; exercises requiring synthesis and/or application of concepts are incorporated into the activity.
|
Time ET |
Topic |
Duration
|
|
10:00 – 10:15 am |
Part 1 Global Landscape Overview |
Grace F. Palma |
|
10:15 - 11:25 am |
Part 2 US FDA and Canada Health Start from Design Control to Submission |
Tal Bresler |
|
11:25 – 11:55 am |
Part 3 Cybersecurity Section |
TBD |
|
11:55 am -12:10 pm |
Break |
|
|
12:10 – 12:25 pm |
Part 4 Clinical Data Acceptance |
TBD |
|
12:25 – 1:10 pm |
Part 5 EU Regulatory Framework |
TBD |
|
1:10 – 1:40 pm |
China Regulatory Landscape |
Viki Chen |
|
1:40 – 2:00 pm |
Final Q &A |
All Presenters |
RAPS reserves the right to cancel this program at its sole discretion. RAPS will not be responsible for travel or other costs incurred due to cancellation. All cancellation requests must be submitted in writing to [email protected]. Cancellations will receive a full refund minus a 20% administrative fee. RAPS is unable to accept cancellations by phone.
Paid registration substitutions may be accepted with written approval from RAPS for requests received before the start of the event. To transfer a registration, email [email protected] with the event title, name of the original registrant and the contact information for the new attendee.
A certificate of attendance can be downloaded from the RAPS Learning Portal following the event.
Contact the RAPS Support Center:
Call +1 301 770 2920, ext. 200 (8:30 am–5:30 pm EST, Monday–Friday) or email [email protected].




Principal, China Med Device
Grace Fu Palma is the principal of China Med Device, part of the global market access platform, Accel Groups with offices in US, China and Japan. With representations in key countries, Accel Groups provides one-stop solutions for medical device/IVD companies to enter key countries market with regulatory, clinical, and commercial services. Grace is a seasoned bilingual and bicultural MedTech executive, specializing in China and US regulatory and commercialization services. She has 30 years of experience driving global and China business strategy, regulatory, clinical evaluation and trials, commercialization, partnerships, for both large multinationals and startup companies. She started China Med Device (CMD) in 2011. She has been personally involved in launching hundreds of medical devices in the US and China market. She has extensive network of clinical, regulatory and industry contacts. She founded Chinese American Heart Association in 2005 and Chinese Eye Care Alliance Group. She grew up in Beijing China with joint degree from Beijing University and an MBA from Yale University.
China Med Device
Vicki Chen has 10 years of experience in China NMPA registration across medical devices, SaMD, and IVD products. She specializes in active and passive devices, cardiovascular technologies, and implantable products. Viki has led cross-region coordination of submission documentation between US/EU manufacturers and China local teams, covering type testing execution and NMPA submission deliverables. She has supported on-site NMPA testing at manufacturers’ sites for capital equipment, including IEC safety and EMC testing activities. Plus, she has experience in China Medical Device GMP-related factory audits/inspection readiness, including QMS documentation review, on-site compliance checks, and pre-inspection preparation support. Viki received her MBA from University of Illinois Urbana-Champaign (UIUC) and her BA from Sichuan University.
Co-founder, SpringRA
Tal Bresler-Stramer is the founder and principal of SpringRA, a regulatory affairs consultancy that supports the global commercialization of medical devices and AI-based medical technologies. With over 20 years of experience, Tal has contributed to the clearance and launch of a wide range of medical technologies, including hybrid NM/CT scanners and single-use RF treatment tips. For the past eight years, Tal has worked with companies ranging from start-ups to global manufacturers, providing regulatory strategy and support for both immediate submission needs and long-term planning.
In the last five years, Tal’s work has increasingly focused on AI-driven medical technologies, working closely with research and development teams to align technical innovation with regulatory requirements. This work has included the development and successful FDA submission of AI applications such as image reconstruction algorithms, robotic-assisted systems, and computer-guided navigation platforms. Tal has extensive experience with FDA expectations for artificial intelligence, including dataset curation, algorithm validation, and lifecycle change management.
We have completed our migration to a new platform and are pleased to introduce the updated site.
What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.
We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.
We welcome your feedback. Please let us know how we can continue to improve your experience.